Result
| Gene | Variant | Type | Tumor | Drug | Drug level | Reference | More |
|---|---|---|---|---|---|---|---|
| NOTCH1 | 2245-2536 | MUT | Adenoid Cystic Carcinoma | NOTCH1 inhibitors | IV | 1 | |
|
Evidence region
CGI Patient Criteria- NoteNOTCH1 mutations define a distinct disease phenotype characterized by solid histology, liver and bone metastasis, poor prognosis, and potential responsiveness to Notch1 inhibitors. Clinical studies targeting Notch1 in a genotype-defined ACC subgroup are warranted. Gene name
Full name
notch receptor 1 Gene typeprotein-coding FunctionThis gene encodes a member of the NOTCH family of proteins. Members of this Type I transmembrane protein family share structural characteristics including an extracellular domain consisting of multiple epidermal growth factor-like (EGF) repeats, and an intracellular domain consisting of multiple different domain types. Notch signaling is an evolutionarily conserved intercellular signaling pathway that regulates interactions between physically adjacent cells through binding of Notch family receptors to their cognate ligands. The encoded preproprotein is proteolytically processed in the trans-Golgi network to generate two polypeptide chains that heterodimerize to form the mature cell-surface receptor. This receptor plays a role in the development of numerous cell and tissue types. Mutations in this gene are associated with aortic valve disease, Adams-Oliver syndrome, T-cell acute lymphoblastic leukemia, chronic lymphocytic leukemia, and head and neck squamous cell carcinoma. [provided by RefSeq, Jan 2016] Sorry, there is no related drug information. |
|||||||